Tarik Skubal is a New York Met -- for $450 million over nine years!
It's not often that a two-time Cy Young winner still in his prime and regarded as one of the best starting pitchers in the game becomes available in free agency. These are potential franchise-altering difference-makers, maybe a final piece needed to build a World Series champion. If you have an owner who wants to win and is willing to spend the money, you make it happen at any cost.
Steve Cohen and the New York Mets made it happen, landing Skubal for the largest total value contract ever for a pitcher, surpassing Yoshinobu Yamamoto's 10-year, $325 million deal with the Dodgers. The 30-year-old left-hander needs no introduction: He won Cy Young Awards with the Detroit Tigers in 2024 and 2025, leading the American League in ERA and WAR both seasons. Over the past three seasons, he's gone 43-17 with a 2.42 ERA, ranking first among all pitchers in FanGraphs WAR, second in Baseball-Reference WAR, second in strikeouts, second in ERA, third in strikeout rate, first in strikeout-to-walk ratio, second in lowest walk rate, fourth in batting average allowed, and 10th in home run rate.
Skubal's stuff matches the results: A 97 mph four-seamer (batters have hit .201 against it the past three seasons); a changeup that is considered one of the best in the game and helps him dominate right-handed batters as much as lefties; oh, and a sinker, slider and curveball. He executes with precision and conviction. He's allowed no runs or one run in 44 of his 88 starts over the past three seasons. He should remain a Cy Young contender over much of the life of the contract if he stays healthy. While there are legitimate concerns for position players in their 30s, this is less of an issue for pitchers with this kind of ability: See Chris Sale dominating the past three years in his age 35-to-37 seasons; Max Scherzer recording six top-five Cy Young finishes from age 30 to 36; or Justin Verlander winning Cy Youngs at 36 and 39.
Of course, staying healthy is always the big "if" for any pitcher --and maybe more so for Skubal. His left elbow has been operated on three times, including Tommy John surgery in college and a new, less-invasive procedure in May to remove loose bodies that allowed for a quicker recovery than traditional arthroscopic surgery. He was back pitching in less than two months, looked as good as ever, and posted a 2.61 ERA in 10 starts for the Los Angeles Dodgers after being acquired in a trade deadline blockbuster.
For the Mets, signing Skubal is about more than just signing an ace. It fills a hole in their rotation that has eluded them since Jacob deGrom's peak. They tried Scherzer and Verlander, gave Sean Manaea a big deal, signed Kodai Senga out of Japan and traded for Freddy Peralta last offseason. None were really the staff ace the Mets hoped for; DeGrom, in 2020, was the last Mets pitcher to finish in the top five of the Cy Young voting. Now the Mets can line up Skubal with Nolan McLean, who finished fourth in the NL Rookie of the Year voting after posting a 3.16 ERA, and Christian Scott to headline a rotation that is instantly much improved after ranking 23rd in ERA. The Mets might not stop at Skubal to boost this group, either.
The Mets will want to handle Skubal's workload carefully, as the Tigers did. He has made just 26 starts over the past three seasons on four days' rest. They rarely let him go past 100 pitches: four times in 2024, three times in 2025 and none in 2026 (although the Dodgers let him do it three times). Skubal is so efficient -- racking up strikeouts but keeping his pitch total low -- that he still usually goes six or seven innings and, really, his usage pattern isn't any different from the other top starters' in today's baseball.
Still, that's one reason I'm stopping short of the more obvious "A" for signing the top free agent of the offseason: In general, starting pitchers just aren't as valuable as they once were. Sure, one can point to Yamamoto's Herculean performance in the 2025 postseason, when he threw two complete games -- Skubal has one his entire career -- and then pitched in relief in Game 7.
Skubal isn't about to throw 98 pitches and then 34 more in relief the next day. But he has been excellent in the postseason with a 2.13 ERA in eight starts, though his teams are just 4-4 in those games.
For the most part, recent World Series runs have been more often fueled by bullpens than starting pitchers -- see the Braves in 2021, the Astros in 2022, the Dodgers in 2024 and certainly the Brewers in 2026.
The bigger reason I can't quite give this the highest grade is simply the size of the contract: No matter the success of pitchers like Sale, Scherzer and Verlander in their 30s, this is an enormous risk for the Mets -- on top of Juan Soto's $765 million contract, which still has 13 years to go. No matter what happens in terms of a salary cap in the upcoming labor negotiations, that's a huge percentage of payroll going to just two players, even if they are superstars. The Mets can't afford either player to falter or decline much in upcoming years.
The final part of the equation: Are the Mets close to competing for a title? They weren't in 2026, when they finished 74-88. Sure, Soto missed 50 games, and there's hope that young outfielders Carson Benge and A.J. Ewing will be even better (they were just the fourth pair of rookie outfielders on the same team to post 3.0 WAR). But holes remain in the bullpen, at first base, at second base and even third base if Bo Bichette doesn't play better. Skubal is a huge piece of the puzzle -- but not necessarily the final piece the Mets will need.

